IP Library › Granted Patent US 10,822,379
Granted Patent B1
US 10,822,379 · App. 15/931,939 · Granted Nov 3, 2020

Molecules that bind to SARS-CoV-2

Inventors: Dimiter Stanchev Dimitrov (Pittsburgh, PA); Chuan Chen (Pittsburgh, PA); Dontcho V. Jelev (Rockville, MD); John W. Mellors (Pittsburgh, PA); Wei Li (Pittsburgh, PA); Zehua Sun (Pittsburgh, PA)
Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
C07K14/165A61K39/15A61K39/395C07K2317/56C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,822,379
App. No.
15/931,939
Granted
Nov 3, 2020
Kind
B1
Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) to a SARS-CoV-2 antigen. For example, binders (e.g., antibodies, antigen binding fragments, and antibody domains) that bind to a SARS-CoV-2 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having COVID-19 (or a viral infection caused by SARS-CoV-2) are provided.

Claims (28)

1. An isolated antibody comprising:

(i) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a light chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11;

(ii) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, and a light chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27;

(iii) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:73, SEQ ID NO:74, and SEQ ID NO:75; or

(iv) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:89, SEQ ID NO:90, and SEQ ID NO:91.

2. The isolated antibody of claim 1 , wherein said isolated antibody comprises said heavy chain variable domain or region and said light chain variable domain or region of said (i).

3. The isolated antibody of claim 1 , wherein said isolated antibody comprises said heavy chain variable domain or region and said light chain variable domain or region of said (ii).

4. The isolated antibody of claim 1 , wherein said isolated antibody comprises said heavy chain variable domain or region of said (iii).

5. The isolated antibody of claim 1 , wherein said isolated antibody comprises said heavy chain variable domain or region of said (iv).

6. The isolated antibody of claim 1 , wherein said isolated antibody is an isolated monoclonal antibody.

7. An isolated antigen binding fragment comprising:

(i) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a light chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11;

(ii) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, and a light chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27;

(iii) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:73, SEQ ID NO:74, and SEQ ID NO:75; or

(iv) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:89, SEQ ID NO:90, and SEQ ID NO:91.

8. The isolated antigen binding fragment of claim 7 , wherein said isolated antigen binding fragment comprises said heavy chain variable domain or region and said light chain variable domain or region of said (i).

9. The isolated antigen binding fragment of claim 7 , wherein said isolated antigen binding fragment comprises said heavy chain variable domain or region and said light chain variable domain or region of said (ii).

10. The isolated antigen binding fragment of claim 7 , wherein said isolated antigen binding fragment comprises said heavy chain variable domain or region of said (iii).

11. The isolated antigen binding fragment of claim 7 , wherein said isolated antigen binding fragment comprises said heavy chain variable domain or region of said (iv).

12. The isolated antigen binding fragment of claim 7 , wherein said isolated antigen binding fragment is an isolated monoclonal antigen binding fragment.

13. The isolated antigen binding fragment of claim 7 , wherein said isolated antigen binding fragment is an Fab.

14. An isolated antibody domain comprising:

(i) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:73, SEQ ID NO:74, and SEQ ID NO:75; or

(ii) a heavy chain variable domain or region comprising the amino acid sequences set forth in SEQ ID NO:89, SEQ ID NO:90, and SEQ ID NO:91.

15. The isolated antibody domain of claim 14 , wherein said isolated antibody domain comprises said heavy chain variable domain or region of said (i).

16. The isolated antibody domain of claim 14 , wherein said isolated antibody domain comprises said heavy chain variable domain or region of said (ii).

17. The isolated antibody domain of claim 14 , wherein said isolated antibody domain is an isolated monoclonal antibody domain.

18. The isolated antibody domain of claim 14 , wherein said isolated antibody domain is a VH domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2020
From: DIMITROV, DIMITER STANCHEV; CHEN, CHUAN; JELEV, DONTCHO V.; MELLORS, JOHN W.; LI, WEI; SUN, ZEHUA
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 053296/0810 →
Continuity (1)
Provisional Application 62988856 · Mar 12, 2020
Cited By (7)
US 12,251,440 US 12,421,300 US 12,496,470 US 12,534,513 US 12,560,598 US 12,630,890 US 12,716,892